Skip navigation | ||
|
||
Medical Encyclopedia |
|
Other encyclopedia topics: | A-Ag Ah-Ap Aq-Az B-Bk Bl-Bz C-Cg Ch-Co Cp-Cz D-Di Dj-Dz E-Ep Eq-Ez F G H-Hf Hg-Hz I-In Io-Iz J K L-Ln Lo-Lz M-Mf Mg-Mz N O P-Pl Pm-Pz Q R S-Sh Si-Sp Sq-Sz T-Tn To-Tz U V W X Y Z 0-9 |
Contents of this page: | |
|
|
Alternative Names Return to top
Waldenstrom's macroglobulinemia; Macroglobulinemia - primary; Lymphoplasmacytic lymphomaDefinition Return to top
Macroglobulinemia of Waldenstrom is a cancer of the B lymphocytes (a type of white blood cell). Such cancer is called lymphoplasmacytic lymphoma. It is associated with the overproduction of proteins called IgM antibodies.
Causes Return to top
The cause of the overproduction of the IgM antibody is unknown. Overproduction of IgM causes the blood to become too thick. This is called hyperviscosity. It makes it harder for blood to flow through small blood vessels.
About 1,500 people in the United States are diagnosed with Waldenstrom's macroglobulinemia every year. Most people with this condition are over age 65, however, it may occur in younger people.
Symptoms Return to top
Additional symptoms that may be associated with this disease:
Exams and Tests Return to top
A physical examination may reveal a swollen spleen, liver, and lymph nodes. An eye exam may show enlarged veins in the retina or retinal bleeding (hemorrhages).
A CBC shows a low number of red bloods and platelets. A blood chemistry shows evidence of kidney disease. A serum viscosity test can tell if the blood has become thick. Symptoms usually occur when the blood is four times thicker than normal.
A test called serum protein electrophoresis shows an increased amount of the IgM antibody. Levels seen in Waldenstrom's macroglobulinemia are generally greater than 3 g/dL.
Bone lesions are very rare. If they are present, a bone marrow examination will show cells that resemble both lymphocytes and plasma cells.
Additional tests that may be done:
Treatment Return to top
Plasmapheresis (plasma exchange) removes unwanted substances from the blood. In macroglobulinemia, it removes or reduces the high level of IgM, and is used to quickly control the symptoms caused by blood thickening.
Drug therapy may include steroids, Leukeran, Alkeran, Cytoxan, fludarabine, or rituximab.
Patients who have a low number of red or white blood cells or platelets may need transfusions or antibiotics.
Outlook (Prognosis) Return to top
The average survival is about 5 years. In some people, the disorder may produce few symptoms and progress slowly.
Possible Complications Return to top
When to Contact a Medical Professional Return to top
Call your health care provider if symptoms of this disorder develop.
References Return to top
Ferri FF. Ferriās Clinical Advisor: Instant Diagnosis and Treatment. 8th ed. St. Louis, Mo: Mosby; 2006:909.
Goldman L, Ausiello D. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa: WB Saunders; 200:1068, 1992.
Update Date: 9/20/2006 Updated by: Corey Cutler, MD, MPH, FRCP(C), Assistant Professor of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Review provided by VeriMed Healthcare Network.
Home | Health Topics | Drugs & Supplements | Encyclopedia | Dictionary | News | Directories | Other Resources | |
Copyright | Privacy | Accessibility | Quality Guidelines U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894 National Institutes of Health | Department of Health & Human Services |
Page last updated: 02 January 2008 |